The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

Kamalesh Sankhala, Alain Mita, Kevin Kelly, Devalingam Mahalingam, Francis Giles, Monica Mita*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

87 Scopus citations


Mammalian target of rapamycin (mTOR) has emerged as an important target for cancer therapy. Rapamycin has a distinct, well-documented toxicity profile and most of the toxicity data has been reported in patients with organ transplantation. Newer mTOR inhibitors have slightly different pharmacokinetic properties, yet they present toxicity profiles similar to rapamycin. Most of these toxicities are mild to moderate in severity and can be managed clinically by dose modification and supportive measures. Mucositis and pneumonitis are the most commonly reported toxicities, but they rarely lead to treatment discontinuation. Pathogenesis of pneumonitis is uncertain, but various hypotheses have been suggested, including cell-mediated immune response to the drug.

Original languageEnglish (US)
Pages (from-to)135-142
Number of pages8
JournalTargeted Oncology
Issue number2
StatePublished - Apr 2009


  • Hyperlipidemia
  • MTOR inhibitors
  • Mucositis
  • Newer mTOR inhibitors
  • Pulmonary toxicity
  • Rapamycin
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Cancer Research


Dive into the research topics of 'The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents'. Together they form a unique fingerprint.

Cite this